Celldex Therapeutics Inc. logo

Celldex Therapeutics Inc.

CLDX | NASDAQ
Chart Builder DCF Calculator
$37.89
-$0.35 (-0.92%)
At close: Sep 21, 2026, 4:00 PM ET
$31.69
-$6.20 (-16.36%)
Pre-market: Sep 22, 2026, 8:44 AM ET

Market Data

Market Cap
$2.52B
Enterprise Value
$1.81B
Beta
0.84
Average Volume
919.76K
Shares Outstanding (Diluted)
77.84M
Shares Change YoY
17.24%
Institutional Ownership
N/A
Exchange
NASDAQ
ISIN
US15117B2025

Price Performance

Price Change 1M
-5.5%
Price Change 3M
14.9%
Price Change 6M
19.6%
Price Change YTD
40.3%
Price Change 1Y
52.4%
Price Change 3Y
48.9%
Price Change 5Y
-31.4%
1M CAGR (ann.)
-9.2%
1Y CAGR (ann.)
46.2%
5Y CAGR (ann.)
-6.9%
All-Time CAGR
-9.2%

Valuation

PE Ratio
-8.69
Forward PE
N/A
PEG Ratio
0.25
Forward PEG
-7.87
PS Ratio
22,510.20
Forward PS
256.90
PB Ratio
3.53
P/FCF Ratio
-8.16
P/Adj. FCF Ratio
-7.16
P/OCF Ratio
-12.50
EV/Sales
16,146.96
EV/EBIT
-7.96
EV/EBITDA
-8.05
EV/FCF
-5.85
Earnings Yield
-11.5%
FCF Yield
-12.3%
Adj. FCF Yield
-14.0%

Financial Health

Net Cash
$717.59M
Total Debt
$4.9M
Cash & Short-Term Investments
$717.59M
Total Assets
$782.35M
Current Ratio
11.82
Quick Ratio
11.82
Debt / Equity Ratio
0.01
Debt / EBITDA
-0.02
Debt / FCF
-0.02
OCF / Debt
-61.41
Interest Coverage
0.00
Altman Z-Score
18.86
Piotroski F-Score
1

Margins & Profitability

Gross Profit Margin
-56850.9%
Operating Profit Margin
-218963.4%
EBITDA Margin
-265353.6%
Net Profit Margin
-268385.7%
FCF Margin
-275932.1%
Adj. FCF Margin
-314471.4%
SBC / Revenue
30929.5%
SBC Impact (per share)
-14.0%

Returns

Return on Assets
-38.4%
Return on Equity
-52.4%
Return on Invested Capital
-45.1%
Return on Capital Employed
-45.2%
Return on Tangible Assets
-39.8%

Historical Growth (CAGR)

Revenue CAGR 3Y
-67.5%
Revenue CAGR 5Y
-58.0%
Revenue CAGR 10Y
-32.3%
EPS CAGR 3Y
-24.0%
EPS CAGR 5Y
-17.2%
EPS CAGR 10Y
23.2%
FCF CAGR 3Y
-45.1%
FCF CAGR 5Y
-32.7%
FCF CAGR 10Y
-16.3%

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
19
EPS Growth Next 3Y
29.9%
Revenue Growth Next 3Y
1521.7%
Earnings Date
Nov 8, 2026
EPS Estimate (next Q)
-$1.02
EPS Growth Est (next Q)
1.0%
Revenue Est (next Q)
$722.64K
Revenue Growth Est (next Q)
N/A

Fair Value Estimates

Graham Number
N/A
Graham Upside
N/A
Lynch Fair Value
N/A
Lynch Upside
N/A
Price Target
$63.88
Price Target Upside
68.6%

Cash Flow

Operating Cash Flow
$-301.15M
Free Cash Flow
$-309.04M
Adj. Free Cash Flow
$-352.21M
FCF Per Share
-$3.11
OCF Per Share
-$3.03
OCF/S Ratio
-210326.8%

Income Statement

Revenue
$112K
Gross Profit
$-63.7M
Operating Income
$-245.24M
EBITDA
$-224.6M
Net Income
$-300.59M
EPS (Diluted)
-$4.36
Revenue / Employee
$565.66
Profit / Employee
$-1.52M
Employees
198

© 2026 bestshares.com. All rights reserved.